Race to the finish: pharma edges closer to approval with RSV vaccines
Pharmaceutical Technology
FEBRUARY 1, 2023
RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. In 2022, the EMA approved AstraZeneca and Sanofi’s monoclonal antibody therapy Beyfortus (nirsevimab ) for RSV protection in all infants.
64 
Let's personalize your content